We regret to report that long term Biogen Inc. (NASDAQ:BIIB) shareholders have had that experience, with the share price dropping 20% in three years, versus a market return of about 89%.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

At $310.58, the average BIIB stock price target of $310.58 suggests a modest upside potential of 1.8% from current levels. Biogen stock has rallied over 27% so far this year. IQVIA Holdings (IQV ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 30% over the last three months. Given the company's impressive performance, we decided to study its ...

VIDEO: Nasdaq 100 Movers: BIIB, GILD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session. This move lagged the S&P 500's daily loss of 0.74%. Elsewhere, the Dow lost 0.9% ...

BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

That downside risk was realized by Biogen Inc. (NASDAQ:BIIB) shareholders over the last year, as the share price declined 15%. That's well below the market return of 60%.

VIDEO: Nasdaq 100 Movers: MSTR, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.